163 related articles for article (PubMed ID: 34295653)
1. PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer.
Wu F; Gu Y; Kang B; Heskia F; Pachot A; Bonneville M; Wei P; Liang J
Transl Lung Cancer Res; 2021 Jun; 10(6):2441-2451. PubMed ID: 34295653
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry.
Yoon JY; Nayyar R; Quest G; Pabedinskas D; Pal P; Tsao MS; Schwock J; Ko HM
Lung Cancer; 2020 Oct; 148():55-61. PubMed ID: 32799091
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
[TBL] [Abstract][Full Text] [Related]
4. Enrichment of circulating tumor-derived extracellular vesicles from human plasma.
Yoh KE; Lowe CJ; Mahajan S; Suttmann R; Nguy T; Reichelt M; Yang J; Melendez R; Li Y; Molinero L; Ruppel J; Xu W; Plaks V
J Immunol Methods; 2021 Mar; 490():112936. PubMed ID: 33242493
[TBL] [Abstract][Full Text] [Related]
5. Harmonization across programmed death ligand 1 (PD-L1) assays for lung cancer by immunohistochemistry using noncontact alternating current electric field mixing.
Matsuo T; Imai K; Nanjo H; Takashima S; Hiroshima Y; Atari M; Kuriyama S; Ishii Y; Wakamatsu Y; Sato Y; Motoyama S; Matsumura Y; Suzuki H; Nomura K; Minamiya Y
Thorac Cancer; 2021 Apr; 12(8):1187-1194. PubMed ID: 33650770
[TBL] [Abstract][Full Text] [Related]
6. Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer.
Saito Y; Horiuchi S; Morooka H; Ibi T; Takahashi N; Ikeya T; Shimizu Y; Hoshi E
J Thorac Dis; 2019 Dec; 11(12):4982-4991. PubMed ID: 32030214
[TBL] [Abstract][Full Text] [Related]
7. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
8. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
9. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
Tsunoda A; Morikawa K; Inoue T; Miyazawa T; Hoshikawa M; Takagi M; Mineshita M
BMC Cancer; 2019 Jun; 19(1):546. PubMed ID: 31174496
[TBL] [Abstract][Full Text] [Related]
10. Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.
Pan Y; Zheng D; Li Y; Cai X; Zheng Z; Jin Y; Hu H; Cheng C; Shen L; Wang J; Ji H; Sun Y; Zhou X; Chen H
J Thorac Dis; 2017 Aug; 9(8):2579-2586. PubMed ID: 28932565
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
Yoneshima Y; Ijichi K; Anai S; Ota K; Otsubo K; Iwama E; Tanaka K; Oda Y; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Apr; 118():36-40. PubMed ID: 29572000
[TBL] [Abstract][Full Text] [Related]
12. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer.
Song Z; Cheng G; Zhang Y
J Thorac Dis; 2020 Apr; 12(4):1385-1392. PubMed ID: 32395276
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory.
Vigliar E; Malapelle U; Iaccarino A; Acanfora G; Pisapia P; Clery E; De Luca C; Bellevicine C; Troncone G
J Clin Pathol; 2019 Jun; 72(6):412-417. PubMed ID: 30846480
[TBL] [Abstract][Full Text] [Related]
15. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
[No Abstract] [Full Text] [Related]
16. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
17. Blood exosome PD-L1 is associated with PD-L1 expression measured by immunohistochemistry, and lymph node metastasis in lung cancer.
Zhang Z; Jin W; Xu K; Zheng X; Zhou Y; Luo M; Yan C; Zheng X; Jin E
Tissue Cell; 2022 Dec; 79():101941. PubMed ID: 36228365
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer.
Hwang DM; Albaqer T; Santiago RC; Weiss J; Tanguay J; Cabanero M; Leung Y; Pal P; Khan Z; Lau SCM; Sacher A; Torlakovic E; Cheung C; Tsao MS
J Thorac Oncol; 2021 Sep; 16(9):1490-1500. PubMed ID: 33915250
[TBL] [Abstract][Full Text] [Related]
19. Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma.
Li JW; Shi D; Wan XC; Hu J; Su YF; Zeng YP; Hu ZJ; Yu BH; Zhang QL; Wei P; Zhou XY
Oncoimmunology; 2021; 10(1):1995166. PubMed ID: 34745768
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis of
Huang RSP; Decker B; Murugesan K; Hiemenz M; Mata DA; Li G; Creeden J; Ramkissoon SH; Ross JS
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34130989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
